The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials
Abstract
BACKGROUND: Direct-to-consumer prescription drug ads typically fail to provide fundamental information that consumers need to make informed decisions: data on how well the drug works. OBJECTIVE: To see whether providing consumers with a drug facts box-a table quantifying outcomes with and without the drug-improves knowledge and affects judgments about prescription medications. DESIGN: Two randomized, controlled trials conducted between October 2006 and April 2007: a symptom drug box trial using direct-to-consumer ads for a histamine-2 blocker and a proton-pump inhibitor to treat heartburn, and a prevention drug box trial using direct-to-consumer ads for a statin and clopidogrel to prevent cardiovascular events. SETTING: National sample of U.S. adults identified by random-digit dialing. PARTICIPANTS: Adults age 35 to 70 years who completed a mailed survey; the final samples comprised 231 participants with completed surveys in the symptom drug box trial (49% response rate) and 219 in the prevention drug box trial (46% response rate). INTERVENTION: In both trials, the control group received 2 actual drug ads (including both the front page and brief summary). The drug box group received the same ads, except that the brief summary was replaced by a drug facts box. MEASUREMENTS: Choice between drugs (primary outcome of the symptom drug box trial) and accurate perceptions of drug benefits and side effects (primary outcome of the prevention drug box trial). RESULTS: In the symptom drug box trial, 70% of the drug box group and 8% of the control group correctly identified the PPI as being "a lot more effective" than the histamine-2 blocker (P < 0.001), and 80% and 38% correctly recognized that the side effects of the 2 drugs were similar (P < 0.001). When asked what they would do if they had bothersome heartburn and could have either drug for free, 68% of the drug box group and 31% of the control group chose the proton-pump inhibitor, the superior drug (P < 0.001). In the prevention drug box trial, the drug box improved consumers' knowledge of the benefits and side effects of a statin and clopidogrel. For example, 72% of the drug box group and 9% of the control group correctly quantified the benefit (absolute risk reduction) of the statin (P < 0.001). Most of the control participants overestimated this benefit, and 65% did so by a factor of 10 or more. LIMITATIONS: The trials tested drug boxes in only 4 direct-to-consumer ads. If other direct-to-consumer ads were to communicate outcome data better, the effect of the drug box would be reduced. CONCLUSION: A drug facts box improved U.S. consumers' knowledge of prescription drug benefits and side effects. It resulted in better choices between drugs for current symptoms and corrected the overestimation of benefit in the setting of prevention. PRIMARY FUNDING SOURCE: National Cancer Institute and Attorney General Consumer and Prescriber Education Program.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Dennis, M. S. (1996) · The Lancet · Cited by 2,728
The Role of Numeracy in Understanding the Benefit of Screening Mammography
Schwartz, L. M., Woloshin, S., Black, W. C., & Welch, H. G. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-11-199712010-00003 · Cited by 1,130
Self-citationChanges in Telephone Survey Nonresponse over the Past Quarter Century
Curtin, R., Presser, S., & Singer, E. (2005) · Public Opinion Quarterly · doi:10.1093/poq/nfi002 · Cited by 925
Gauging the Impact of Growing Nonresponse on Estimates from a National RDD Telephone Survey
Keeter, S., Kennedy, C., Dimock, M., Best, J., & Craighill, P. (2006) · Public Opinion Quarterly · doi:10.1093/poq/nfl035 · Cited by 902
Kravitz, R. L., Epstein, R. M., Feldman, M. D., Franz, C. E., Azari, R., Wilkes, M. S., Hinton, L., & Franks, P. (2005) · JAMA · doi:10.1001/jama.293.16.1995 · Cited by 586
Sigterman, K. E., van Pinxteren, B., Bonis, P. A., Lau, J., & Numans, M. E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002095.pub5 · Cited by 507
Frosch, D. L., Krueger, P. M., Hornik, R. C., Cronholm, P. F., & Barg, F. K. (2007) · The Annals of Family Medicine · doi:10.1370/afm.611 · Cited by 256
Cited by
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Col, N. F., Bennett, C. L., Barry, M. J., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub4 · Cited by 1,471
Progress in evidence-based medicine: a quarter century on
Djulbegovic, B., & Guyatt, G. H. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31592-6 · Cited by 1,022
Decision aids for people facing health treatment or screening decisions
Stacey, D., Bennett, C. L., Barry, M. J., Col, N. F., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Légaré, F., & Thomson, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub3 · Cited by 849
Hoffmann, T. C., & Del Mar, C. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.6016 · Cited by 707
Metadata
- Authors
- Schwartz, L. M., Woloshin, S., & Welch, H. G.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2009-04-21
- Volume
- 150
- Issue
- 8
- Pages
- 516-527
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2166467489
- Cited by
- 256
- References
- 19
- FWCI
- 17.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials. https://app.cochat.ai/papers/10.7326/0003-4819-150-8-200904210-00106
- The paper
- Schwartz, L. M., Woloshin, S., & Welch, H. G. (2009). Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-150-8-200904210-00106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.